Urology-Specific eClinical Quality Measure Accepted for 2018 MIPS Reporting
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy Approved
CHICAGO, Ill., Nov. 6, 2017 – LUGPA, the leading association for urologists in independent practice, today announced that its urology-specific electronic Clinical Quality Measure (eCQM) was approved by CMS and will go into effect Jan. 1, 2018. The new quality measure will allow the electronic reporting of a bone-density screening for men who are prescribed androgen-deprivation therapy (ADT) with the intent to treat for a year or longer, as men on ADT often experience a loss in bone mass. The measure was developed by LUGPA member, Oregon Urology Institute (OUI) with support and review from LUGPA and association member, Skyline Urology.
While directly impacting clinics and clinicians, the measure will also alleviate the burden on all urologists of submitting reports under the Merit-based Incentive Payment System (MIPS). In fact, OUI and LUGPA are the first urologic entities to develop urology-specific eCQM’s for MIPS reporting, which will benefit all practicing urologists.
“eClinical Quality Measures are key to maintaining a high quality of care, and this urology-specific measure paves the way for all urologists to pursue best practices that streamline administrative processes and advance quality of care for patients,” said Neal D. Shore, MD, FACS, president of LUGPA. “It is our priority to be at the forefront of initiatives in value-based care, with the goal of advancing the practice of urology. This measure helps advance that goal.”
LUGPA continues to work on the development of additional urology-specific eCQM’s for purposes of MIPS reporting. The pipeline of additional measures under development include:
- Use of active surveillance for low-risk prostate cancer;
- Urinary Symptom score change 6-12 months after diagnosis of benign prostatic hyperplasia;
- Treatment of osteopenia or osteoporosis in men with non-metastatic prostate cancer on androgen deprivation therapy; and
- Intravesical bacillus calmette-guerinutilization for non-muscle invasive bladder cancer.
“We took the initiative to develop an eClinical Quality Measure because we saw a need that would benefit all men who are prescribed androgen-deprivation therapy (ADT) for more than a year,” said Bryan A. Mehlhaff, MD, Research Medical Director at Oregon Urology Institute and LUGPA Board Member. “When OUI engaged LUGPA for review and support, we created a fantastic process that reaffirmed LUGPA and its members as leaders in value-based urologic care.”
The implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) Quality Payment Program by CMS advances the federal government’s transition from fee-for service reimbursement models to a focus on value-based care. The MIPS payment track combines existing programs that measure and evaluate medical outcomes. “The electronic measures developed by LUGPA and the Oregon Urology Institute will enable urologists to take advantage of electronic reporting of quality measures, and serve as a gateway for more urologic-specific measures to be developed in the future. These efforts will assist urology’s transition to value-based care,” noted Dr. Shore.
LUGPA is a trade Association that represents independent urology group practices in the U.S., with more than 2,300 physicians who make up more than 25 percent of the nation’s practicing urologists, and provide more than 30 percent of the total urologic care in the U.S. The Association is committed to providing the best resources and information for its member practices through advocacy, research, data collection and benchmarking efforts. LUGPA advocates for independent urology practices by promoting quality clinical outcomes, fostering new opportunities and improving advocacy in the legislative and regulatory arenas. For more information, visit lugpa.org. To learn more about electronic clinical quality measures, visit https://ecqi.healthit.gov/ecqms.